Nanomedicines in B cell-targeting therapies

• Published in: Acta biomaterialia Vol. 137; pp. 1 - 19
• Main Authors: Wang, Jiawei, Yang, Jiyuan, Kopeček, Jindřich
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.01.2022; Elsevier BV
• Subjects: Antigens; Autoimmune diseases; Autoimmunity; B cell targeting; B-cell receptor; Blood circulation; Cell survival; Depletion; Drug carriers; Drug delivery; Drug Delivery Systems; Humans; Immune checkpoint; Immunosuppressive agents; Immunotherapy; Low molecular weights; Lymphocytes; Lymphocytes B; Lymphocytes T; Molecular weight; Nanomedicine; Nanomedicines; Nanotechnology; Neoplasms - drug therapy; Toxicity; Weight reduction; Autoimmunity; B cell targeting; Immunotherapy; Nanomedicines
• ISSN: 1742-7061; 1878-7568
• DOI: 10.1016/j.actbio.2021.10.024

B cells play multiple roles in immune responses related to autoimmune diseases as well as different types of cancers. As such, strategies focused on B cell targeting attracted wide interest and developed intensively. There are several common mechanisms various B cell targeting therapies have relied on, including direct B cell depletion, modulation of B cell antigen receptor (BCR) signaling, targeting B cell survival factors, targeting the B cell and T cell costimulation, and immune checkpoint blockade. Nanocarriers, used as drug delivery vehicles, possess numerous advantages to low molecular weight drugs, reducing drug toxicity, enhancing blood circulation time, as well as augmenting targeting efficacy and improving therapeutic effect. Herein, we review the commonly used targets involved in B cell targeting approaches and the utilization of various nanocarriers as B cell-targeted delivery vehicles. As B cells are engaged significantly in the development of many kinds of diseases, utilization of nanomedicines in B cell depletion therapies have been rapidly developed. Although numerous studies focused on B cell targeting have already been done, there are still various potential receptors awaiting further investigation. This review summarizes the most relevant studies that utilized nanotechnologies associated with different B cell depletion approaches, providing a useful tool for selection of receptors, agents and/or nanocarriers matching specific diseases. Along with uncovering new targets in the function map of B cells, there will be a growing number of candidates that can benefit from nanoscale drug delivery. [Display omitted]